Ligand Pharmaceuticals (LGND) Equity Income (2016 - 2020)
Historic Equity Income for Ligand Pharmaceuticals (LGND) over the last 6 years, with Q1 2020 value amounting to -$25.5 million.
- Ligand Pharmaceuticals' Equity Income fell 24720.41% to -$25.5 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$39.9 million, marking a year-over-year decrease of 19265.69%. This contributed to the annual value of $2.9 million for FY2019, which is 9394.02% down from last year.
- Latest data reveals that Ligand Pharmaceuticals reported Equity Income of -$25.5 million as of Q1 2020, which was down 24720.41% from $8.5 million recorded in Q4 2019.
- Ligand Pharmaceuticals' Equity Income's 5-year high stood at $59.9 million during Q3 2018, with a 5-year trough of -$74.0 million in Q4 2018.
- In the last 5 years, Ligand Pharmaceuticals' Equity Income had a median value of -$1.2 million in 2017 and averaged $180705.9.
- Within the past 5 years, the most significant YoY rise in Ligand Pharmaceuticals' Equity Income was 597546.61% (2018), while the steepest drop was 175817.65% (2018).
- Quarter analysis of 5 years shows Ligand Pharmaceuticals' Equity Income stood at -$9.0 million in 2016, then soared by 149.64% to $4.5 million in 2017, then crashed by 1758.18% to -$74.0 million in 2018, then soared by 111.46% to $8.5 million in 2019, then crashed by 400.19% to -$25.5 million in 2020.
- Its last three reported values are -$25.5 million in Q1 2020, $8.5 million for Q4 2019, and -$10.5 million during Q3 2019.